Pneumococcal conjugate second or third-dose vaccines (PCVc) in Low income (World Bank)
Low income (World Bank): Pneumococcal conjugate second or third-dose vaccines (PCVc) was 68.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Low income (World Bank), 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
In 2025, pneumococcal conjugate second or third-dose vaccines (pcvc) in Low income (World Bank) stood at 68.0%. That is the highest value across all 18 years on record.
The figure is up 9.7% on the previous year and up 13.3% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Low income (World Bank) peaked at 68.0% in 2019 and was at its lowest, 0.0%, in 2008.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Low income (World Bank), year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 2.0% | — |
| 2011 | 10.0% | +400.0% |
| 2012 | 22.0% | +120.0% |
| 2013 | 34.0% | +54.5% |
| 2014 | 54.0% | +58.8% |
| 2015 | 60.0% | +11.1% |
| 2016 | 64.0% | +6.7% |
| 2017 | 67.0% | +4.7% |
| 2018 | 67.0% | +0.0% |
| 2019 | 68.0% | +1.5% |
| 2020 | 66.0% | -2.9% |
| 2021 | 62.0% | -6.1% |
| 2022 | 64.0% | +3.2% |
| 2023 | 62.0% | -3.1% |
| 2024 | 62.0% | +0.0% |
| 2025 | 68.0% | +9.7% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 44.8% | 2.0% | 68.0% | 10 |
| 2020s | 64.0% | 62.0% | 68.0% | 6 |
Countries ranked near Low income (World Bank)
- 11 Turkmenistan 98.0% compare
- 11 El Salvador 98.0% compare
- 11 Portugal 98.0% compare
- 11 Costa Rica 98.0% compare
- 11 Saudi Arabia 98.0% compare
- 11 Mauritius 98.0% compare
More health data for Low income (World Bank)
- Pertussis - number of reported cases 16,008 (2025)
- Diphtheria - number of reported cases 7,814 (2025)
- Measles - number of reported cases 197,977 (2025)
- Total tetanus - number of reported cases 5,130 (2025)
- Neonatal tetanus - number of reported cases 1,406 (2025)
- Infant mortality rate (probability of dying between birth and age 1) 46.69 (2024)
- Number of neonatal deaths 537,523 (2024)
- Thinness among children and adolescents, BMI-for-age < -2 standard 7.6% (2024)
- Under-five mortality rate 68.8 (2024)
- Neonatal mortality rate 24.94 (2024)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Low income (World Bank)?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Low income (World Bank) was 68.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Low income (World Bank)?
- The highest recorded value was 68.0% in 2019.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Low income (World Bank)?
- The lowest recorded value was 0.0% in 2008.
- How does Low income (World Bank) rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Low income (World Bank) ranks 8th out of 11 groups with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Low income (World Bank)?
- Over the last ten years it is up 13.3%. The long-run trend across the full record is volatile.
- Where does this Low income (World Bank) data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).